CCM
KRTX

Copernicus Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Copernicus Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-26,000
Closed -$1.96M – 20
2019
Q4 		$1.96M Buy
+26,000
New +$1.14M 2.57% 12

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Copernicus Capital Management's KRTX Position: Q1 2020 in Review

Copernicus Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2020, closing a stake of 26,000 shares — an estimated $1.96M sold.

Copernicus Capital Management first reported a position in KRTX in Q4 2019 and held it in 1 quarter. The position peaked at $1.96M in Q4 2019. 99 funds tracked by Wall St. Rank hold KRTX as of Q1 2020.

  • Copernicus Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Copernicus Capital Management sold 26,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $1.96M.
  • Copernicus Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Copernicus Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1.96M in Q4 2019.
  • 99 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Copernicus Capital Management's 13F filing for Q1 2020, filed 14 May 2020.